New Study Also Finds AMD Agents Equal (CME/CE)
(MedPage Today) -- A head-to-head comparison between bevacizumab (Avastin) and ranibizumab (Lucentis) for wet age-related macular degeneration adds to mounting evidence that both agents are equals in improving visual acuity, British researchers reported.